Weekly Prediction: 17 - 23 Jan, Express News Service. Read More. Microsoft and partners may be compensated if you purchase something through recommended links in this article. Found the story interesting? Like us on Facebook to see similar stories. I am already a fan, don't show this again.
Send MSN Feedback. How can we improve? Click here to join our channel indianexpress and stay updated with the latest headlines. Must Read. Pilot disorientation due to weather change led to CDS chopper crash: Court of Inquiry IED found in unattended bag in Delhi, NSG carries out controlled explosion Covid cases dip in Delhi, but so do testing numbers Buoyed by inductions, Akhilesh now faces ticket claims from turncoats, SP aspirants Bishop Franco Mulakkal acquitted in Kerala nun rape, verdict draws chorus of outrage Collision between two India-bound flights averted during take-off at Dubai airport No running away from our batting collapses every now and then: Virat Kohli Why the East India Company opposed Christian missionary activity in India Australia cancels Novak Djokovic's visa again.
D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient API and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial. As per the clinical trial protocol approved, subjects with mild COVID will be randomised in the study in a ratio to Molnupiravir with the standard of care, or standard of care alone.
The treatment duration is a maximum of 05 days and the total study duration will be a maximum of 28 days from randomisation.
The interim results on patients have shown promising results of Molnupiravir. Vascular medicine rotated-square. Diabetes rotated-square. Cardiovascular rotated-square. Haematology rotated-square.
0コメント